Boston Scientific led a $95.4m Series C round in Anumana.

Boston Scientific, a US-based medical device company, led a $95.4m Series C round in Anumana, an AI-driven health technology company focused on cardiovascular care, with participation from Mayo Clinic, Matrix Capital Management, Matrix Partners, and NTT Venture Capital. “This new investment is a strong validation of Anumana’s strategic direction and momentum. We’ve built a solid foundation in diagnostic cardiology AI, and we’re now extending that expertise into the perioperative setting. By applying generative AI to imaging and intraoperative support, we’re creating intuitive offerings to interpret complex data in real time and facilitate delivery of care,” Maulik Nanavaty, Anumana CEO.